Opus Genetics CFO Gagnon sells 14,000 shares
The chief financial officer’s sale covered tax-withholding obligations tied to restricted stock unit vesting and settlement and was described as non-discretionary.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Opus Genetics, Inc. (IRD) Chief Financial Officer Robert E. Gagnon sold 14,000 shares of common stock on October 23, 2026, at a weighted average price of $3.5464 per share, leaving 542,375 shares held directly. The sale was made under a Rule 10b5-1 trading plan adopted April 30, 2026. The shares sold covered tax-withholding obligations arising from restricted stock unit vesting and settlement; the footnote states the transaction was not discretionary. Sale prices ranged from $3.4449 to $3.79 per share.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 14,000 | $3.5464 | $50K |
Footnotes (2)
- F1. The shares reported on this line were sold were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer. The shares sold cover tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units. This transaction does not represent a discretionary trade by the Reporting Person.
- F2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $3.4449 to $3.79, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
restricted stock units financial
tax withholding obligations financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.